Fig. 3

ZRANB2 strengthened the malignant behaviors of glioma cells by stabilizing SNHG20. a RNA-IP confirmed the binding interaction between ZRANB2 and SNGH20. Relative enrichment was measured by qRT-PCR; data are presented as mean ± SD (n = 3, each group). ^**P < 0.01 vs. anti-normal IgG respective group. b The graph shows nascent SNHG20 in U87 and U251 cells; data are presented as mean ± SD (n = 3, each group). c The graph shows SNHG20 levels at different times treated by ActD in U87 and U251 cells (regulated by ZRANB2); data are presented as mean ± SD (n = 3, each group). ^**P < 0.01 vs. ZRANB2(−)-NC group, ^##P < 0.01 vs. ZRANB2(+)-NC group. d Protein levels of MMP1, MMP9 and VE-Cadherin regulated by ZRANB2 and SNHG20 in U87 and U251 cells. Representative protein expressions and corresponding IDVs of MMP1, MMP9, VE-Cadherin in U87 and U251 are shown; data are presented as mean ± SD (n = 3, each group). ^*P < 0.05 vs. ZRANB2(−) + SNHG20(+) group, ^**P < 0.01 vs. ZRANB2(−) + SNHG20(+) group, ^#P < 0.05 vs. ZRANB2(+) + SNHG20(−) group, ^##P < 0.01 vs ZRANB2(+) + SNHG20(−) group. e CCK-8 assay was used to measure the effect of proliferation on U87 and U251 cells by ZRANB2 and SNHG20. Data are presented as mean ± SD (n = 3, each group). ^**P < 0.01 vs. ZRANB2(−) + SNHG20(+) group, ^##P < 0.01 vs. ZRANB2(+) + SNHG20(−) group. f Transwell assay was used to measure the effect of migration and invasion on U87 and U251 cells by ZRANB2 and SNHG20. Representative images and corresponding statistical plots are shown. Data are presented as mean ± SD (n = 3, each group). ^**P < 0.01 vs. ZRANB2(−) + SNHG20(+) group, ^##P < 0.01 vs ZRANB2(+) + SNHG20(−) group. Scale bars indicate 50 μm. g Three-dimensional culture was used to measure the effect of VM on U87 and U251 cells by ZRANB2 and SNHG20. Representative images and corresponding statistical plots are shown. Data are presented as mean ± SD (n = 3, each group). ^*P < 0.05 vs. ZRANB2(−) + SNHG20(+) group, ^#P < 0.05 vs. ZRANB2(+) + SNHG20(−) group. Scale bars indicate 50 μm